Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -21.30% is 100% below its 1-year average of -10.65%, near the low end of its 1-year range (-21.30%–0.00%).
As of the fiscal period ended Wednesday, December 31, 2025. 100.00% below its 12-month average of -10.65%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.38%.
RETURN ON ASSETS (ROA)
-21.30%
RETURN ON ASSETS (ROA) AVG TTM
-10.65%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+33.93%
vs the sector median at left
Alamar Biosciences, Inc.
Market Cap
$2.24B
Return on Assets (ROA)
-21.30%
TTM Avg
-10.65%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.28B
Return on Assets (ROA)
13.20%
TTM Avg
13.52%
3Y Avg
17.46%
5Y Avg
11.53%
Market Cap
$2.17B
Return on Assets (ROA)
-53.05%
TTM Avg
-52.17%
3Y Avg
-43.79%
5Y Avg
-37.43%
Market Cap
$2.17B
Return on Assets (ROA)
-12.82%
TTM Avg
-15.67%
3Y Avg
-7.42%
5Y Avg
-2.36%
Market Cap
$2.30B
Return on Assets (ROA)
26.56%
TTM Avg
-38.82%
3Y Avg
-43.93%
5Y Avg
-45.44%
Market Cap
$2.13B
Return on Assets (ROA)
-22.09%
TTM Avg
-8.08%
3Y Avg
-39.70%
5Y Avg
-49.84%
Market Cap
$2.34B
Return on Assets (ROA)
10.60%
TTM Avg
9.82%
3Y Avg
10.45%
5Y Avg
8.86%
Market Cap
$2.35B
Return on Assets (ROA)
-63.74%
TTM Avg
-33.67%
3Y Avg
-37.78%
5Y Avg
-31.10%
Market Cap
$2.36B
Return on Assets (ROA)
24.69%
TTM Avg
32.00%
3Y Avg
9.13%
5Y Avg
-4.32%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.24B | -21.30% | -10.65% | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 13.20% | 13.52% | 17.46% | 11.53% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | -53.05% | -52.17% | -43.79% | -37.43% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -12.82% | -15.67% | -7.42% | -2.36% |
| Liquidia Corporation (LQDA)vs › | $2.30B | 26.56% | -38.82% | -43.93% | -45.44% |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | -22.09% | -8.08% | -39.70% | -49.84% |
| UFP Technologies, Inc. (UFPT)vs › | $2.34B | 10.60% | 9.82% | 10.45% | 8.86% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -63.74% | -33.67% | -37.78% | -31.10% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 24.69% | 32.00% | 9.13% | -4.32% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.23% | 5.94% | 5.72% | 5.23% |
ROA
-21.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -21.30% |
| 2024-12-31 | 0.00% |
